Genotype - phenotype correlation in an adolescent girl with pathogenic PPARy genetic variation that caused severe hypertriglyceridemia and early onset type 2 diabetes
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Severe hypertriglyceridemia (HTG) (>885 mg/dL) can be caused by familial partial lipodystrophy type 3 (FPLD3), an autosomal dominant disorder caused by loss of function of the peroxisome proliferator-activated receptor gamma (PPARG), characterized by abnormal distribution of fat and metabolic derangements. This case reports a 16-year-old female (body mass index, 23.5 kg/m2) hospitalized twice for pancreatitis (triglycerides [TG] level >2,200 mg/dL). Her treatment management included bowel rest, insulin infusion, and plasmapheresis. A low-fat diet with 10 g of fat daily and 160 mg of fenofibrate daily decreased fasting TG to 411 mg/dL (range, 0–149 mg/dL). The patient had a normal leptin level. Panel testing of genes that impact TG metabolism revealed a known pathogenic variant in the PPARG gene (c.452A>G p.Tyr151Cys). A second variant detected in this gene, c.1003G>C (p.Val335Leu), is considered benign. Her glycosylated hemoglobin of 6.6% and 2-hour oral glucose tolerance test confirmed type 2 diabetes mellitus (T2DM). This study reports the earliest detection of T2DM in an adolescent with a pathogenic variant of PPARG. PPARG-related FPLD3 should be considered in lean children that present with severe HTG and insulin resistance, and subsequent treatment with proliferator-activated receptor gamma agonists, specifically thiazolidinediones, should be considered.
Abstract
Severe hypertriglyceridemia (HTG) (>885 mg/dL) can be caused by familial partial lipodystrophy type 3 (FPLD3), an autosomal dominant disorder caused by loss of function of the peroxisome proliferator-activated receptor gamma (PPARG), characterized by abnormal distribution of fat and metabolic derangements. This case reports a 16-year-old female (body mass index, 23.5 kg/m2) hospitalized twice for pancreatitis (triglycerides [TG] level >2,200 mg/dL). Her treatment management included bowel rest, insulin infusion, and plasmapheresis. A low-fat diet with 10 g of fat daily and 160 mg of fenofibrate daily decreased fasting TG to 411 mg/dL (range, 0–149 mg/dL). The patient had a normal leptin level. Panel testing of genes that impact TG metabolism revealed a known pathogenic variant in the PPARG gene (c.452A>G p.Tyr151Cys). A second variant detected in this gene, c.1003G>C (p.Val335Leu), is considered benign. Her glycosylated hemoglobin of 6.6% and 2-hour oral glucose tolerance test confirmed type 2 diabetes mellitus (T2DM). This study reports the earliest detection of T2DM in an adolescent with a pathogenic variant of PPARG. PPARG-related FPLD3 should be considered in lean children that present with severe HTG and insulin resistance, and subsequent treatment with proliferator-activated receptor gamma agonists, specifically thiazolidinediones, should be considered.
참고문헌 (20)
- Peters JM, "Localization of the gene for familial partial lipodystrophy(Dunnigan variety)to chromosome 1q21-22", Nat Genet, 18, pp.292~295 (1998)
- Barroso I, "Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension", Nature, 402, pp.880~883 (1999)
- Gandotra S, "Perilipin deficiency and autosomal dominant partial lipodystrophy", N Engl J Med, 364, pp.740~748 (2011)
- Spiegelman BM, "PPAR-gamma : adipogenic regulator and thiazolidinedione receptor", Diabetes, 47, pp.507~514 (1998)
- Nawrocki AR, "Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists", J Biol Chem, 281, pp.2654~2660 (2006)
- Visser ME, "Characterisation of nonobese diabetic patients with marked insulin resistance identifies a novel familial partial lipodystrophyassociated PPARgamma mutation(Y151C)", Diabetologia, 54, pp.1639~1644 (2011)
- Akinci B, "Clinical presentations, metabolic abnormalities and end-organ complications in patients with familial partial lipodystrophy", Metabolism, 72, pp.109~119 (2017)
- Majithia AR, "Rare variants in PPARG with decreased activity in adipocyte differentiation are associated with increased risk of type 2 diabetes", Proc Natl Acad Sci U S A, 111, pp.13127~13132 (2014)
- Richards S, "Standards and guidelines for the interpretation of sequence variants : a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology", Genet Med, 17, pp.405~424 (2015)
- Broekema MF, "Gene-gene and gene-environment interactions in lipodystrophy : lessons learned from natural PPARγmutants", Biochim Biophys Acta Mol Cell Biol Lipids, 1864, pp.715~732 (2019)
- Majithia AR, "Prospective functional classification of all possible missense variants in PPARG", Nat Genet, 48, pp.1570~1575 (2016)
- Hegele RA, "The polygenic nature of hypertriglyceridaemia : implications for definition, diagnosis, and management", Lancet Diabetes Endocrinol, 2, pp.655~666 (2014)
- Berberich AJ, "Conservative management in hypertriglyceridemia-associated pancreatitis", J Intern Med, 286, pp.644~650 (2019)
- Henderson SR, "Severe hypertriglyceridaemia in Type 2 diabetes mellitus : beneficial effect of continuous insulin infusion", QJM, 106, pp.355~359 (2013)
- Näsström B, "Lipoprotein lipase during continuous heparin infusion : tissue stores become partially depleted", J Lab Clin Med, 138, pp.206~213 (2001)
- Haque WA, "Risk factors for diabetes in familial partial lipodystrophy, Dunnigan variety", Diabetes Care, 26, pp.1350~1355 (2003)
- Savage DB, "Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma", Diabetes, 52, pp.910~917 (2003)
- Francis GA, "Peroxisomal proliferator activated receptor-gamma deficiency in a Canadian kindred with familial partial lipodystrophy type 3(FPLD3)", BMC Med Genet, 7, pp.3~ (2006)
- Demir T, "Familial partial lipodystrophy linked to a novel peroxisome proliferator activator receptor-γ(PPARG)mutation, H449L : a comparison of people with this mutation and those with classic codon 482 Lamin A", C(LMNA)mutations, 2016, pp.33, 1445~1450
- Agostini M, "A pharmacogenetic approach to the treatment of patients with PPARG mutations", Diabetes, 67, pp.1086~1092 (2018)